FI965019A0 - Enzym-inhibitorer - Google Patents

Enzym-inhibitorer

Info

Publication number
FI965019A0
FI965019A0 FI965019A FI965019A FI965019A0 FI 965019 A0 FI965019 A0 FI 965019A0 FI 965019 A FI965019 A FI 965019A FI 965019 A FI965019 A FI 965019A FI 965019 A0 FI965019 A0 FI 965019A0
Authority
FI
Finland
Prior art keywords
enzyme inhibitors
protecting group
amidino
intermediates
chem
Prior art date
Application number
FI965019A
Other languages
English (en)
Finnish (fi)
Other versions
FI965019A (sv
Inventor
Harold Francis Hodson
Richard Michael John Palmer
David Alan Sawyer
Richard Graham Knowles
Karl Witold Franzmann
Martin James Drysdale
Steven Smith
Patricia Ifeyinwa Davies
Helen Alice Rebecca Clark
Barry George Shearer
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509774.7A external-priority patent/GB9509774D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI965019A0 publication Critical patent/FI965019A0/sv
Publication of FI965019A publication Critical patent/FI965019A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FI965019A 1994-06-15 1996-12-13 Enzym-inhibitorer FI965019A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94304314 1994-06-15
GBGB9509774.7A GB9509774D0 (en) 1995-05-15 1995-05-15 Enzyme inhibitors
PCT/GB1995/001378 WO1995034534A1 (en) 1994-06-15 1995-06-14 Enzyme inhibitors

Publications (2)

Publication Number Publication Date
FI965019A0 true FI965019A0 (sv) 1996-12-13
FI965019A FI965019A (sv) 1996-12-13

Family

ID=26137155

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965019A FI965019A (sv) 1994-06-15 1996-12-13 Enzym-inhibitorer

Country Status (29)

Country Link
US (2) US5889056A (sv)
EP (2) EP0957087B1 (sv)
JP (2) JP2989010B2 (sv)
KR (1) KR100430207B1 (sv)
CN (1) CN1070849C (sv)
AT (2) ATE229001T1 (sv)
AU (1) AU692892B2 (sv)
BR (1) BR9507995A (sv)
CA (1) CA2192668A1 (sv)
CY (2) CY2238B1 (sv)
DE (2) DE69529101T2 (sv)
DK (2) DK0957087T3 (sv)
ES (2) ES2145282T3 (sv)
FI (1) FI965019A (sv)
GR (1) GR3033746T3 (sv)
HK (1) HK1003935A1 (sv)
HU (1) HUT77407A (sv)
IL (2) IL114142A (sv)
IS (1) IS4384A (sv)
MX (1) MX9606136A (sv)
MY (1) MY115437A (sv)
NO (1) NO308655B1 (sv)
NZ (1) NZ289157A (sv)
PT (2) PT765308E (sv)
RU (1) RU2162841C2 (sv)
SI (2) SI0957087T1 (sv)
TW (1) TW442453B (sv)
WO (1) WO1995034534A1 (sv)
ZA (1) ZA954940B (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740339B1 (fr) * 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
US6620848B2 (en) 1997-01-13 2003-09-16 Smithkline Beecham Corporation Nitric oxide synthase inhibitors
US6369272B1 (en) 1997-01-13 2002-04-09 Glaxosmithkline Nitric oxide synthase inhibitors
US6160021A (en) * 1997-02-04 2000-12-12 The General Hospital Corporation Method for treating epidermal or dermal conditions
AU8647198A (en) * 1997-08-12 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for diseases associated with bone resorption
GEP20043179B (en) * 1998-03-11 2004-02-25 Searle & Co Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) * 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
AU6605800A (en) * 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
DE60116067T2 (de) * 2000-03-24 2006-08-31 Pharmacia Corp., Chicago Amidino-verbindungen als hemmstoffe der stickstoffmonoxid-synthase
AR034120A1 (es) * 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
GB0031179D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10111054A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10111049A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111052A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
MXPA04011335A (es) * 2002-05-16 2005-07-01 Pharmacia Corp Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
GB0214147D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Formulations
WO2004080956A1 (en) * 2003-03-11 2004-09-23 Pharmacia Corporation S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
JP5298008B2 (ja) 2006-04-20 2013-09-25 グラクソ グループ リミテッド 新規化合物
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CA2724726C (en) 2008-05-23 2018-02-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
SG174452A1 (en) 2009-03-19 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
US20120035237A1 (en) 2009-04-24 2012-02-09 Diane Mary Coe Pyrazole and triazole carboxamides as crac chann el inhibitors
MX2011011534A (es) 2009-04-30 2012-02-28 Glaxo Group Ltd Indazoles sustituidos por oxazol como inhibidores de cinasa pi3.
CN102639494B (zh) * 2009-10-09 2016-11-09 扎夫根公司 砜化合物及其制备和使用方法
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
US9670194B2 (en) 2013-09-22 2017-06-06 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
EP3122728A4 (en) 2014-03-28 2017-10-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514450A1 (de) 1985-04-22 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von imidaten sowie neue arylsubstituierte imidate
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE4310202A1 (de) 1992-03-30 1993-10-07 Ciba Geigy µ-Ketoimidoester als Stabilisatoren für chlorhaltige Polymerisate
FR2727111B1 (fr) * 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments

Also Published As

Publication number Publication date
HK1003935A1 (en) 1998-11-13
NO965379L (no) 1996-12-13
EP0765308B1 (en) 2000-04-05
JP2989010B2 (ja) 1999-12-13
IS4384A (is) 1996-11-13
ATE191470T1 (de) 2000-04-15
AU2891795A (en) 1996-01-05
IL114142A (en) 2000-02-17
NZ289157A (en) 1998-03-25
EP0957087B1 (en) 2002-12-04
GR3033746T3 (en) 2000-10-31
KR100430207B1 (ko) 2004-07-19
PT765308E (pt) 2000-09-29
MY115437A (en) 2003-06-30
CA2192668A1 (en) 1995-12-21
EP0957087A3 (en) 2000-12-20
TW442453B (en) 2001-06-23
SI0765308T1 (en) 2000-08-31
DE69529101T2 (de) 2003-11-13
ZA954940B (en) 1996-12-17
US5889056A (en) 1999-03-30
ATE229001T1 (de) 2002-12-15
DE69516141T2 (de) 2000-10-19
DK0957087T3 (da) 2003-03-24
ES2189322T3 (es) 2003-07-01
JP3614711B2 (ja) 2005-01-26
CY2455B1 (en) 2005-06-03
MX9606136A (es) 1998-06-30
CY2238B1 (en) 2003-07-04
WO1995034534A1 (en) 1995-12-21
CN1155276A (zh) 1997-07-23
JP2000026402A (ja) 2000-01-25
FI965019A (sv) 1996-12-13
DE69516141D1 (de) 2000-05-11
DK0765308T3 (da) 2000-09-11
HUT77407A (hu) 1998-04-28
CN1070849C (zh) 2001-09-12
USRE39576E1 (en) 2007-04-17
IL128717A0 (en) 2000-01-31
HU9603454D0 (en) 1997-02-28
PT957087E (pt) 2003-04-30
NO965379D0 (no) 1996-12-13
IL114142A0 (en) 1995-10-31
BR9507995A (pt) 1997-08-05
AU692892B2 (en) 1998-06-18
EP0765308A1 (en) 1997-04-02
JPH10506371A (ja) 1998-06-23
DE69529101D1 (de) 2003-01-16
ES2145282T3 (es) 2000-07-01
SI0957087T1 (en) 2003-04-30
EP0957087A2 (en) 1999-11-17
RU2162841C2 (ru) 2001-02-10
NO308655B1 (no) 2000-10-09

Similar Documents

Publication Publication Date Title
ATE191470T1 (de) Enzymhemmer
DE69416848D1 (en) Amidino-derivate als no-synthetase inhibitoren
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
WO1998028282A3 (en) OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
DK0471236T3 (da) Imidazopyridinderivater og deres anvendelse
DE60228316D1 (en) Xanthinoxidaseinhibitoren
DE69522703D1 (de) Aminotetrazol-derivate verwendbar als stickstoff-oxid-synthase inhibitoren
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
EP0277725A3 (en) 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents
DZ1724A1 (fr) Nouvelles azétidinones substituées comme agents anti-inflammatoires et anti-dégénérescence.
BG103520A (en) The use of aminothiazoles as microbicides
AP9400608A0 (en) "New nicotinic acid derivative".
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DK1423385T3 (da) Mellemprodukter til fremstilling af neuraminidaseinhibitorkonjugater

Legal Events

Date Code Title Description
FD Application lapsed